1-6 of 6
Jane N. Winter, M.D.
Close
Sort by
Journal Articles

A Phase I/II Trial of Combination Gemcitabine and Bortezomib (VELCADE®) for Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma (NHL) and Aggressive B-Cell NHL

Andrew M. Evens, DO, MSc, Steven T. Rosen, MD, FRCPA, Leo I. Gordon, MD, FACP, Irene Helenowski, MS, Justin Kline, MD, Annette Larsen, B.A., R.N., Jane N. Winter, M.D., Sonali M. Smith, MD, Koen M. Van Besien, MD
Journal: Blood
Blood (2011) 118 (21): 1646.
https://doi.org/10.1182/blood.V118.21.1646.1646
Published: 2011
Journal Articles

Bortezomib May Be Safely Combined with Y-90 Ibritumomab Tiuxetan In Patients with Relapsed/Refractory Follicular or Transformed Non-Hodgkin Lymphoma: A Phase I Trial of Combined Induction Therapy and Bortezomib Consolidation

Rupali Roy, M.D., Andrew M Evens, DO, MSc, David P. Patton, B.S., Annette Larsen, B.S., R.N., Alfred Rademaker, Ph.D., Jeffrey Cilley, M.D., Stewart Spies, M.D., Daina Variakojis, M.D., Leo I Gordon, M.D., Jane N. Winter, M.D.
Journal: Blood
Blood (2010) 116 (21): 1749.
https://doi.org/10.1182/blood.V116.21.1749.1749
Published: 2010
Journal Articles

PILLAR-1: Preliminary Results of a Phase II Study of mTOR Inhibitor Everolimus In Patients with Mantle Cell Lymphoma (MCL) Who Are Refractory or Intolerant to Bortezomib

Owen A. O'Connor, MD, PhD, Leslie Popplewell, M.D., Jane N. Winter, M.D., RuiRong Yuan, MD, PhD, Anna Robeva, MS, Helene Cauwel, Quincy Chau, Michael Wang, MD
Journal: Blood
Blood (2010) 116 (21): 3963.
https://doi.org/10.1182/blood.V116.21.3963.3963
Published: 2010
Journal Articles

Triggered Release of Nanoparticulate Arsenic Trioxide for Treatment of Malignant Lymphomas: Preclinical Studies

Jane N. Winter, M.D., Dawn Waterhouse, Ph.D., Richard Ahn, Haimei Chen, Leo I. Gordon, M.D., Borko Jovanovic, Ph.D., Marcel Bally, Ph.D., Thomas O’Halloran, Ph.D.
Journal: Blood
Blood (2008) 112 (11): 4989.
https://doi.org/10.1182/blood.V112.11.4989.4989
Published: 2008
Journal Articles

90 Y Ibritumomab Tiuxetan (Zevalin®; 90YZ) Doses Higher Than .4 mCi/kg May Be Safely Combined with High-Dose Beam and Autotransplant: The Role for Dosimetry.

Jane N. Winter, M.D., David J. Inwards, M.D., Stewart Spies, M.D., Gregory Wiseman, M.D., David Patton, William Erwin, M.S., Alfred Rademaker, Ph.D., Stephanie F. Williams, M.D., Martin S. Tallman, M.D., Ivana Micallef, M.D., Jayesh Mehta, M.D., Seema Singhal, M.D., Michael Zimmer, Ph.D., Arturo Molina, M.D., Christine White, M.D., Leo I. Gordon, M.D.
Journal: Blood
Blood (2004) 104 (11): 1162.
https://doi.org/10.1182/blood.V104.11.1162.1162
Published: 2004
Journal Articles

Treatment Response to Single Agent Sphingosomal Vincristine in Patients with Relapsed and/or Refractory Diffuse Aggressive Non-Hodgkin’s Lymphoma (NHL): Subgroup Analyses.

Maria Alma Rodriguez, M.D., Jane N. Winter, M.D.
Journal: Blood
Blood (2004) 104 (11): 2488.
https://doi.org/10.1182/blood.V104.11.2488.2488
Published: 2004